Erodible coatings based on HPMC and cellulase for oral time-controlled release of drugs.
Cellulase
Enzymatic degradation
Hydroxypropyl methylcellulose
Press-coating
Pulsatile release
Swellable/erodible delivery systems
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
30 Jul 2020
30 Jul 2020
Historique:
received:
17
03
2020
revised:
06
05
2020
accepted:
08
05
2020
pubmed:
31
5
2020
medline:
4
3
2021
entrez:
31
5
2020
Statut:
ppublish
Résumé
Oral drug delivery systems for time-controlled release, intended for chronotherapy or colon targeting, are often in the form of coated dosage forms provided with swellable/soluble hydrophilic polymer coatings. These are responsible for programmable lag phases prior to release, due to their progressive hydration in the biological fluids. When based on high-viscosity polymers and/or manufactured by press-coating, the performance of functional hydroxypropyl methylcellulose (HPMC) layers was not fully satisfactory. Particularly, it encompassed an initial phase of slow release because of outward diffusion of the drug through a persistent gel barrier surrounding the core. To promote erosion of such a barrier, the use of a cellulolytic product (Sternzym® C13030) was here explored. For this purpose, the mass loss behavior of tableted matrices based on various HPMC grades, containing increasing percentages of Sternzym® C13030, was preliminarily studied, highlighting a clear and concentration-dependent effect of the enzyme especially with high-viscosity polymers. Subsequently, Sternzym® C13030-containing systems, wherein the cellulolytic product was either incorporated into a high-viscosity HPMC coating or formed a separate underlying layer, were manufactured. Evaluated for release, such systems gave rise to more reproducible profiles, with shortened lag phases and reduced diffusional release, as compared to the reference formulation devoid of enzyme.
Identifiants
pubmed: 32473374
pii: S0378-5173(20)30409-9
doi: 10.1016/j.ijpharm.2020.119425
pii:
doi:
Substances chimiques
Delayed-Action Preparations
0
Tablets
0
Acetaminophen
362O9ITL9D
Hypromellose Derivatives
3NXW29V3WO
Cellulase
EC 3.2.1.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119425Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.